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A b s t r a c t  
The poor solubility of drug substances in water and their low dissolution rate in aqueous G.I.T fluid 
often leads to insufficient bioavailability. The present investigation is an attempt to improve the 
solubility and dissolution rate of diacerein (a poorly soluble drug) by solid dispersion technique. 
Binary solid dispersions were made using PEG-4000 or PEG-6000 as carriers with varying drug: 
carrier ratios 1:1, 1:3 and 1:5. Also ternary solid dispersions were made using PEG-4000 and 
Pluronic F-68 at ratios 1:5:1, 1:5:2 and 1:5:3. Nine formulae were prepared and evaluated for 
saturated solubility, in-vitro drug release. Solid state characterization including DSC, FTIR, XRD and 
SEM is also carried out. All formulae showed marked significant improvement in the solubility and 
dissolution rate of the drug. The interaction studies showed no interaction between the drug and any 
of the used carriers. Formula SD9 (1:5:3; drug: PEG-4000: Pluronic F-68) showed the best 
dissolution profile with about 44.73% of the drug being released in the first 5 minutes and more than 
79 % of the drug being released in the first 15 minutes. Also this formula showed the highest 
dissolution rate of 6.66 %/min. It was concluded that combination of PEG-4000 and Pluronic F-68 
can be well utilized to improve the solubility of poorly soluble drugs. 
Keywords:Diacerein, Solid dispersion, Polyethylene glycol, Physicochemical characterization; In-
vitro dissolution. 
Introduction 
Discovering a way to increase the solubility of poorly water soluble 
drugs in order to improve their pharmaceutical and biological 
availability still remains one of the major technological problems.  
The current status of scientific development having highly variable 
oral bioavailability due to low solubility and dissolution rate in the 
gastrointestinal absorption of many new drugs [1]. 
Even though there are many methods intended to solve the 
problem from which, the formulation of solid dispersion is one of 
the ideal methods of dissolution enhancement. The solid 
dispersions is a dispersion of one or more active ingredients in an 
inert carrier or matrix, prepared by the melting, solvent, or melting 
solvent method. Solid dispersions have been explored as potential 
delivery systems for many poorly soluble drugs such as 
griseofulvin, indomethacin and oxazepam [2].  
 The ability of solid dispersions to afford drug release as fine, 
dispersed particles has resulted in improvements in dissolution 
rates of poorly water soluble drugs which have also been reflected 
in increases in oral bioavailability [3]. A significant particle size 
reduction can be obtained by manufacturing solid dispersions and 
in many cases the drug is molecularly dispersed in the carrier. 
Conversion of the physicochemical state of the drug, e.g. from  
 
 
crystalline to amorphous as well as solubilization and 
supersaturation by the carrier, can cause an increase in the kinetic 
solubility and the dissolution rate [4].  
Diacerein (chemically 4,5-diacetoxy-9,10-dioxo-9,10- 
dihydroanthracene-2-carboxylic acid) a non-steroidal anti-
inflammatory having a chondroprotective action is used in the 
treatment of osteoarthritis [5,6].  
Diacerein lacks cyclooxygenase inhibitory activity and hence has 
no effect on prostaglandin synthesis. It is a selective inhibitor of 
interleukin-1 with a protective effect on granuloma induced 
cartilage breakdown by its reduction of the concentration of pro 
inflammatory cytokines [7,8]. However, its poor aqueous solubility 
and hence limited dissolution makes the bioavailability of the drug 
to be 35-56% of the total dose (50mg) and thus it results in a 
limited therapeutic response [9,10].  
The present work was conducted to improve the dissolution of 
diacerein using solid dispersion technique with PEGs. Pluronic F-
68 (which is non-ionic amphiphilic surfactant) was used in some 
formulations in an attempt to increase drug wettability, solubility 
and hence drug dissolution. 
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Materials 
Diacerein was obtained as a gift sample from (EVA pharm, Egypt), 
Polyethylene glycols grades 4000 and 6000 were purchased from 
Fluka (Switzerland) and Pluronic F-68 was purchased from Sigma-
Aldrich (USA). All other chemicals and solvents were of analytical 
grades. 
Phase solubility study 
Phase solubility study was performed according to the method 
described by Higuchi and Connors [11]. Diacerein in excess 
amounts was added to 20 ml of different concentrations of PEG-
4000 and PEG-6000 in glass stoppered flasks. The concentrations 
used were 0.05%, 0.1%, 0.15%, 0.2%, 0.25% and 3% w/v in 
phosphate buffer pH 7. Flasks were placed in thermostatically 
controlled shaking water bath (Memmert, France) for 72 hr at 37ÀC. 
After equilibrium, aliquots were withdrawn then passed through a 
millipore filter (0.45 um Sartorious, AG Germany), then analyzed 
using a UVăvisible spectrophotometer at 257 nm after suitable 
dilution. All the data were the average of three determinations. 
The GibbÊs free energy of transfer (Δܩ୲୰º ) value provides 
information about whether the treatment is favorable or unfavorable 
for drug solubilization in aqueous medium. Negative Gibbs free 
energy values indicate improved dissolution [12-13]. Values of 
Δܩ୲୰º  were calculated using the following equation: 
 
ΔG୲୰À  = - 2.303RT Log 
S౥
S౩
                           ā Eq. 1 
 
Where So/Ss is the ratio of the solubility of diacerein in buffer 
solution of polymer to that of the pure buffer media. The value of 
gas constant (R) is 8.31 J.K-1.mol-1 and T is temperature in degree 
kelvin.  
 
Table 1: Composition of different binary and ternary solid 
dispersion formulae. 
 
Phase solubility diagrams were obtained by plotting the solubility of 
diacerein (mole/L), versus the concentrations of the polymers PEG-
4000 and PEG-6000 used (%w/v) the results were presented in 
table 2 and figure 1. The complexation efficiency (C.E) as a 
parameter indicating the solubilization power of the polymers  
 
 
Table 2: Values of complexation efficiency and stability constant of diacerein complexes with PEG-4000 and PEG-6000. 
 
aC.E: Complexation Efficiency,   bK1:1: Stability Constant, ΔࡳܜܚÀ : Gibbs free energy, S.D: Standard Deviation
ratio Drug: Carrier Formula 
No. 
1:1 Diacerein:PEG-4000 SD1 
1:3 Diacerein:PEG-4000 SD2 
1:5 Diacerein:PEG-4000 SD3 
1:1 Diacerein:PEG-6000 SD4 
1:3 Diacerein:PEG-6000 SD5 
1:5 Diacerein:PEG-6000 SD6 
1:5:1 Diacerein:PEG-4000:Pluronic F68 SD7 
1:5:2 Diacerein:PEG-4000:Pluronic F68 SD8 
1:5:3 Diacerein:PEG-4000:Pluronic F68 SD9 
PEG-4000 
conc. (%w/v) 
Diacerein conc.(mole/L)  
Average μ S.D 
Δܩ୲୰À  
kJ/mole at 
37ĈC 
PEG-6000 
conc. (%w/v) 
Diacerein conc.(mole/L) 
Average μ S.D 
Δܩ୲୰À  
kJ/mole at 
37ĈC 
0 0.00011169 μ 0.042 0 0 0.00011169 μ 0.042 0 
0.05 0.00014596 μ 0.021 -689.50 0.05 0.00012237 μ 0.093 -235.37 
0.1 0.00016927 μ 0.011 -1071.24 0.1 0.0001554 μ 0.002 -850.89 
0. 15 0.00020201 μ 0.014 -1526.89 0. 15 0.00017426 μ 0.011 -1146.17 
0.2 0.00025363 μ 0.098 -2113.13 0.2 0.00018425 μ 0.077 -1289.79 
0.25 0.00030399 μ 0.082 -2579.84 0.25 0.00021103 μ 0.090 -1639.42 
0.3 0.00034922 μ 0.005 -2937.23 0.3 0.00022477 μ 0.088 -1801.89 
0.4 0.00034784 μ 0.077 -2723.91 0.4 0.00022227 μ 0.022 -1637.72 
0.5 0.00034686 μ 0.039 -2610.23 0.5 0.00021592 μ 0.012 -1462.38 
0.6 0.00034478 μ 0.057 -2491.31 0.6 0.00021672 μ 0.085 -1274.23 
aC.E = 0.0008 aC.E = 0.0004 
bK1:1 = 8.006 mole-1 bK1:1 = 4.001 mole-1 
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Drug content analysis 
Drug content was determined by dissolving an amount of 100 mg 
of drug SDs in 100 mL phosphate buffer pH 7.4. The solution was 
filtered, suitably diluted and the absorbance was measured 
spectrophotometrically at 257 nm. All experiments were repeated 
in triplicate and presented in table 3. 
 
Table 3: Results of saturated solubility and percentage of drug 
content of diacerein in different solid dispersions formulae. 
aC.E: Complexation Efficiency,   bK1:1: Stability Constant, ΔࡳܜܚÀ : 
Gibbs free energy, S.D: Standard Deviation 
In-vitro drug release 
Pure drug (50 mg) and an amount of solid dispersion equivalent to 
50 mg were sprinkled on the surface of the dissolution medium in a 
dissolution tester, apparatus II (Hanson Research, SR 8 Plus 
model, USA). Dissolution studies of diacerein were performed in 
900 ml phosphate buffer of pH 7.4 and stirring speed of 100 r.p.m 
maintained at 37 μ 0.5ĈC. At appropriate time intervals, aliquots of 
5 ml were withdrawn and measured spectrophotometrically at λmax 
257 nm. Experiments were carried out in triplicate. 
Model Independent Approaches Dissolution efficiency 
(% DE)  
Percent DE at 5 and 15 minutes were calculated for all formulae for 
comparison according to equation 3. The dissolution efficiency 
(DE) is defined as the area under the dissolution curve up to a 
certain time (t), expressed as a percentage of the area of the 
rectangle described by 100% dissolution in the same time. 
 
                                     
ā Eq. 3 
 
 
Initial dissolution rate (%/min) 
To compare dissolution rate enhancement of diacerein from SDs 
formulae, Initial dissolution rate (IDR) was calculated as 
percentage dissolved of drug over the first 5 minutes per minute. 
Similarity factor (f2) and Dis-similarity factor (f1) 
A model-independent, mathematical approach proposed by Moore 
and Flanner for calculating f1 and f2 was used for comparison 
among the dissolution profiles [17]. The f2 and f1 is a measure of 
similarity and dissimilarity factor respectively, between two 
dissolution profiles and is given by equations 4 and 5 respectively.  
                             
Eq. 4 
 
 
                                       
In which n is the number of withdrawal points, Rj is the percentage 
dissolved of reference at the time point t, and Tj is the percentage 
dissolved of test at the time point t. A value of 100 for f 2 suggests 
that test and reference profiles are identical. Values between 50 
and 100 indicate that the dissolution profiles are similar, where as 
smaller values imply an increase in dissimilarity. The difference 
factor (dis-similarity factor f1) measures the percent error between 
two profiles over all time points. The value of f1 is zero when the 
test and drug reference profiles are identical and increase 
proportionally with the dissimilarity between the two dissolution 
profiles. 
Analysis of drug release data 
In-vitro release data were fitted to various kinetic models including 
zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Hixsonă
Crowell cube-root model by employing regression analysis 
techniques to determine the probable drug release mechanism [18, 
19]. 
Solid state characterization 
Differential Scanning Calorimetry (DSC)  
Formula 
No. 
Saturated 
solubility 
(øg/ml) in 
distilled water 
(average μ 
S.D) 
% 
increase 
in 
solubility 
Drug content 
average (%) μ 
S.D 
SD1 339.17 μ 0.23 688.94 99.23 μ 1.21 
SD2 363.28 μ 0.67 745.04 99.52 μ 1.37 
SD3 297.81 μ 0.92 592.74 97.13 μ 0.52 
SD4 264.97 μ 1.33 516.35 101.83 μ 0.05 
SD5 279.55 μ 0.54 550.69 99.17 μ 1.52 
SD6 245.48 μ 0.34 471.03 98.89 μ 0.62 
SD7 384.29 μ 0.61 794.49 98.63 μ 1.01 
SD8 431.83 μ 0.45 904.49 101.13 μ 0.34 
SD9 505.95 μ 0.38 1076.92 100.91 μ 0.69 
Pure 
diacerein 42.99 μ 0.17  
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A differential scanning calorimeter (DSC 60, Shimadzu) was used 
to obtain the DSC curves of diacerein, polymers and some 
selected drug-SDs formulae. Five milligrams samples were placed 
in an aluminum pan and the experiment was carried out under 
nitrogen atmosphere at a flow rate of 40 mL/min and a scanning 
rate of 10ĈC/min in the range of 25-250ĈC. 
FTIR Spectroscopy 
IR spectrum of diacerein, polymers and solid dispersions were 
recorded using Shimadzu FT/IR 5300, IR spectrophotometer in 
scanning range 400 to 4000 cm
‐1
, by KBr disc method.  
Powder X-Ray Diffractometry (PXRD) 
The X-ray powder diffraction patterns were obtained by using 
Philips PW 1700 with Cu K alpha (Lambda) radiation and crystal 
monochromator, voltage of 45 mV and 20 Amp current. The 
diffraction patterns run at 2.4⁰ /min over the 2θ range of 2-50À [20]. 
Scanning Electron Microscopy (SEM) 
Photomicrographs of diacerein and some selected SD formulae 
were obtained by SEM (JSM-6360; JEOL Ltd., Japan). The powder 
were mounted on double-sided adhesive tape and sputtered with 
gold for 2 min using SPI sputter (USA). Scanning electron 
photographs were taken at an accelerating voltage of 15 kV. 
Results and Discussion  
Phase solubility study 
The phase solubility profiles for diacerein in the used PEG-4000 
and PEG-6000 buffered solutions are presented in figure 1 (Phase 
solubility profiles for diacerein dispersion in solutions of PEG-4000 
and PEG-6000). 
They displayed AL type [21] equilibrium phase solubility diagrams 
for diacerein in both solutions, showing that diacerein solubility 
increases linearly as a function of PEG concentrations and soluble 
adsorption complexes were formed without occurrence of 
precipitation in the range of PEG concentrations used till 0.3% w/v 
of the polymer, thereby demonstrating that reaction became more 
favourable as concentration of polymer was increased. The 
enhancement in solubility might be due to hydrophilic nature of 
polymers and surface adsorption of drug on the polymer. 
The stability constant was found to be 8.006 and 4.001 molî1 for 
PEG-4000 and PEG-6000 respectively. The complexation 
efficiency in case PEG-4000 was twofold that of PEG-6000. The 
results are in accordance with the well established formation of 
soluble complexes between water soluble polymeric carriers and 
poorly water soluble drugs [22-25].  
An indication of the process of transfer of diacerein from pure water 
to the aqueous solution of PEG 6000 may be obtained from the 
values of Gibbs free energy change. Table 2 presents the values of 
Gibbs free energy (ΔG୲୰º ) associated with the aqueous solubility of 
diacerein in presence of PEG-4000 and PEG-6000.  
The negative values of ΔG୲୰º  were observed at the treated 
concentrations of the polymers, which reflect the spontaneous 
nature of diacerein solubilization. Also, values decreased with 
increasing concentrations of polymer till 0.3% w/v, thereby 
demonstrating that reaction became more favourable as 
concentration of polymer was increased. Above 0.3% w/v reaction 
became un-favourable as concentration of polymer was increased. 
These values also indicated that the extent of improvement in 
solubility was more with PEG-4000 as compared with PEG-6000. 
Analogous results have been observed with other drugs and have 
been attributed to the formation of weak soluble complexes [18, 26-
27].  
Evaluation of diacerein solid dispersions 
Determination of saturated solubility  
Due to the ability to improve wettability and to solubilize some 
compounds, polyethylene glycols (PEG) have been widely used as 
carriers in SDs. Additional presence of self-emulsifying component 
(Pluronic F-68) improves the water solubility of the active 
ingredient. Moreover, it can also increase the dispersability of 
hydrophobic drug in the hydrophilic carrier during the process of 
solid dispersion formation. Therefore, higher amounts of 
molecularely dispersed substance are expected. 
As shown in table 3, all the tested samples have an increase in 
drug solubility over diacerein. It might be due to either the reduction 
of the crystallinity of drug or the improved wetting of the drug 
particles. Improving the wettability of the hydrophobic drug crystals 
might also occur.  
The order of dissolution enhancement with the prepared systems 
was: SD9 > SD8 > SD7 > SD2 > SD1 > SD3 > SD5 > SD4 > SD6 
> pure drug The saturated solubility of the drug is increased with 
an increase in the concentration of carriers. Among the 
preparations of three carriers, formulae SD9 then SD8 gave the 
best results. Since the saturated solubility of diacerein from formula 
SD9 was 505.95 ug/ml versus 42.99 ug/ml of pure drug with 
1076.92% increase in solubility, while formula SD8 showed 
diacerein solubility of 431.83 ug/ml versus 42.99 ug/ml of pure drug 
with 904.49% increase in solubility. 
It is better to note that, the increase in ratio of Pluronic F68 in 
formulae resulted in an increase in solubility of diacerein and this 
could be explained on the basis of micellar solubilization or by 
increasing the steric hindrance among the particles [27].  
Also it is noted that the formulae containing PEG-4000 showed 
higher solubility than that prepared with PEG-6000 and this may be 
explained by decreased dispersibility and higher viscosity of PEG-
6000 than PEG-4000. 
Drug content  
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Percentage drug content of the formulations was found to be in the 
range of 97.13 μ 0.52 to 101.83 μ 0.05 as shown in table (3). 
In-vitro drug release 
The present study confirmed the advantage of improved aqueous 
solubility of diacerein in its binary and ternary solid dispersions 
form, with better dissolution characteristics.  
Different mechanisms have been suggested for enhanced 
dissolution of drug from solid dispersion, these include: (a) 
molecular dispersions, after carrier dissolution the drug is 
molecularly dispersed in the dissolution medium, a high surface 
area is formed, resulting in an increased dissolution rate and 
consequently improved bioavailability [28-29], (b) a strong 
contribution to the enhancement of drug solubility is related to the 
drug wettability and improved wetting may lead to reduced 
agglomeration and increased surface area [30-31], (c) the 
increased porosity of solid dispersion particles also hastens the 
drug release profile [32-33], (d) the enhancement of drug release 
can usually be achieved using the drug in its amorphous state, 
because no energy is required to break up the crystal lattice during 
the dissolution process [34-36], and/or (e) drugs are presented as 
supersaturated solutions after system dissolution, and it is 
speculated that, if drugs precipitate, it is as a metastable 
polymorphic form with higher solubility than the most stable crystal 
form [29, 37-38]. 
Figure 2 (A, B and C) (In-vitro drug release profile of diacerein solid 
dispersions SD1 to SD9 compared with pure drug) shows the 
dissolution profiles of pure diacerein and its binary and ternary 
solid dispersion mixtures.  
Model Independent Approaches 
The calculated %DE5min, %DE15min and IDR values are presented 
in table 4. The average percentage release of pure drug was 
50.24% in 60 min and it is obvious from %DE 15min of 8.03 and IDR 
of 1.03 %/min that the dissolution of pure diacerein is poor and 
slow and this was attributed to the hydrophobicity of the drug.  
Formulation of diacerein as binary solid dispersion with either PEG-
4000 or PEG-6000 resulted in significant enhancement of diacerein 
dissolution and this is clear from the values of %DE 5min, %DE 15min 
and IDR compared to the pure drug (table 4). The results obtained 
revealed that all binary and ternary solid dispersions of diacerein 
have faster dissolution than pure diacerein. Of note is the fact that 
the extent of enhanced dissolution depended on the concentration 
of the polymer used in the solid dispersion, increasing the polymer  
 
Table 4: Dissolution parameters obtained from dissolution data of different binary and ternary solid dispersion formulae. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%DE 5 min: Percent dissolution efficiency at 5 minutes, %DE 15 min: 
Percent dissolution  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
efficiency at 15 minutes, IDR: Initial dissolution rate, f2: Similarity 
factor, f1: Dis-similarity factor. 
 
 
 Dissolution Parameters 
Formula No. % DE 5min % DE 15min IDR (%/min) 
f2 f1 
Drug 3.12 μ 0.01 8.03 μ 0.22 1.03 μ 0.06 
SD1 26.73 μ 0.12 57.18 μ 1.01 5.73 μ 0.02 14.17 μ 0.02 202.40 μ 2.12 
SD2 34.83 μ 0.09 65.43 μ 0.05 6.12 μ 0.06 11.97 μ 0.05 224.12 μ 2.03  
SD3 31.08 μ 0.14 59.48 μ 0.92 5.58 μ 0.11 14.40 μ 0.23 200.18 μ 1.98 
SD4 20.42 μ 0.08 39.02 μ 0.24 3.65 μ 0.25 24.66 μ 0.24 125.93 μ 1.65 
SD5 29.42 μ 0.08 53.75 μ 0.36 4.88 μ 0.36 17.20 μ 0.26 176.38 μ 1.11 
SD6 18.87 μ 0.13 35.95 μ 0.86 3.38 μ 0.22 27.57 μ 0.91 109.63 μ 2.05 
SD7 38.27 μ 0.05 70.20 μ 0.88 6.06 μ 0.81 11.19 μ 0.15 231.38 μ 1.87 
SD8 41.71 μ 0.02 75.96 μ 0.47 6.49 μ 0.44 9.51 μ 0.36 249.12 μ 1.63 
SD9 44.73 μ 0.05 79.73 μ 0.96 6.66 μ 0.33 8.68 μ 0.66 258.03 μ 1.95 
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concentration leaded to increasing the drug release until certain 
concentration above which the drug release was decreased.  
Formulae prepared with PEG-4000 showed higher dissolution rates 
than those prepared with PEG-6000 and this may be explained on 
the basis of PEG-4000 produced less viscous dispersion and the 
rapid diffusion of the dissolved drug molecules.    
The best results among solid dispersion formulae were ternary 
solid dispersions obtained with PEG-4000 in combination with 
Pluronic F-68 in ratios of 1:5:3, 1:5:2 and 1:5:1 (drug: PEG-4000: 
Pluronic F-68) respectively. The drug release was extremely 
improved with these combinations. Increasing the Pluronic F-68 
ratio in the ternary mixture resulted in more increase in drug 
dissolution as it is clear from the calculated dissolution parameters. 
The rapid dissolution obtained in case of the ternary system can be 
thus explained on the basis that both polymers enhance the 
dissolution by different mechanisms which provide a chance for 
synergism upon combination. 
The formula SD9 (1:5:3; drug: PEG-4000: Pluronic F-68) showed 
the best dissolution profile with about 44.73% of the drug being 
released in the first 5 minutes and more than 79 % of the drug 
being released in the first 15 minutes. Also this formula showed the 
highest dissolution rate of 6.66 %/min. 
Improved wettability of the hydrophobic drug by amphiphilic 
compounds is another alternative mechanism. Amphiphilic 
molecules can modify the surface properties of particles which will 
result in a reduction of the contact angle with water or by formation 
of hydrophilic film around the particles [39]. The enhanced 
dissolution of diacerein from PEG solid dispersion was mainly 
attributed to the formation of microcrystalline dispersion of the drug 
[25]. 
The effect of Pluronic F-68 on the drug dissolution may be 
attributed to the enhanced wettability. Eutectic mixture formation 
was also suggested for Pluronic F-68 solid dispersion with other 
drugs [40]. 
Concerning the similarity factor (f2) and dis-similarity factor (f1) 
values in table (4), it is clear that all the prepared binary and 
ternary solid dispersion mixtures showed significant different 
dissolution profiles from that of pure diacerein. SD9 showed f2 and 
f1 of 8.68 and 258.03 respectively. 
Analysis of drug release data 
Table 5 lists the regression parameters obtained after fitting the 
dissolution release data to various kinetic models. Data fitting was 
done up to 90% of drug release and based on the R2, the model 
that best fit the drug release data was first order model for formulae 
SD1-SD2 and SD8-SD9. While KorsmeyerăPeppas is the best 
fitting model for SD3-SD7 with the values of diffusional exponent 
(n) of less than 0.45, indicating Fickian diffusional phenomena 
[13,18].  
 
Table 5: Kinetic analysis of release data of different binary and ternary solid dispersion formulae. 
 Diacerein SDs formulae 
Model Parameter Drug SD1 SD2 SD3 SD4 SD5 SD6 SD7 SD8 SD9 
Zero order 
K 0.950 2.192 2.272 2.129 1.732 1.992 1.609 2.283 2.361 2.387 
R2 0.9783 0.7224 0.6515 0.6831 0.8524 0.7296 0.8517 0.6085 0.5518 0.508 
First 
K 0.013 0.140 0.203 0.152 0.049 0.111 0.039 0.260 0.352 0.454 
R2 0.9908 0.9978 0.9953 0.9891 0.9575 0.9668 0.9458 0.9957 0.9997 0.999 
Higuchi 
K 6.074 15.580 16.352 15.250 11.997 14.152 11.139 16.526 17.022 17.514 
R2 0.9679 0.8911 0.8413 0.8640 0.9662 0.8931 0.9659 0.8052 0.7471 0.726 
Krosmyer-
Peppas 
K 2.094 46.667 61.163 53.136 25.659 45.640 23.643 70.033 80.750 89.320 
n 0.793 0.188 0.123 0.144 0.285 0.166 0.287 0.086 0.056 0.031 
R2 0.9864 0.9849 0.9936 0.9944 0.9994 0.9992 0.9985 0.9977 0.9965 0.997 
Hixson-
Crowell 
K 0.004 0.025 0.026 0.025 0.013 0.023 0.010 0.026 0.026 0.027 
R2 0.9882 0.9465 0.8968 0.9150 0.9392 0.9219 0.9226 0.8558 0.8075 0.784 
Predicted Model First First First Kros-myer 
Kros-
myer 
Kros-
myer 
Kros-
myer 
Kros-
myer First First 
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The diffraction patterns of pure diacerein shows sharp peaks 
indicating the crystalline state of pure diacerein (figure 5A).  
The binary solid dispersion formula SD3 and ternary solid 
dispersion formula SD9 are exhibit characteristics diffraction peaks  
 
of diacerein but of reduced intensity indicating decreased drug 
crystallinity consequently increased the drug solubility (figure 5 B 
and C). 
 
 
Figure 5: X- Ray Diffractograms of (A) pure diacerein, (B) binary solid dispersion formula SD3 and (C) ternary solid dispersion formula SD9  
 
Scanning electron microscopy 
SEM microphotographs of pure diacerein and its binary and ternary 
solid dispersion formulae are shown in figure 6 (SEM photographs 
of (A) pure diacerein, (B) binary solid dispersion formula SD3 and 
(C) ternary solid dispersion formula SD9). Pure diacerein consisted 
of some large irregular crystals with fine particles. A marked loss of 
the crystalline and irregular shape was detected in SEM 
photomicrographs of its binary and ternary solid dispersion 
formulae. SDs appeared as irregular particles in which the fine 
particles of the drug deposited on the surface of the polymer. 
Therefore, the reduced particle size, increased surface area, and 
the close contact between the hydrophilic carrier and the drug 
might be responsible for the drug improved dissolution rate as was 
observed with SD particles. 
 
 
 
 
 
 
 
 
Figure 6: SEM photographs of (A) pure diacerein, (B) binary solid 
dispersion formula SD3 and (C) ternary solid dispersion formula 
SD9. 
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Conclusion 
The present investigation revealed that the combination of PEG-
4000 and Pluronic F-68 is a proper choice as a carrier to enhance 
the dissolution of diacerein from SDs. Among the ratios used, a  
ternary SD with a 1:5:3 (drug: PEG-4000: Pluronic F-68) ratio was 
found to be optimal because of its superior performance in 
enhancing the dissolution of diacerein. The physicochemical 
characterization of solid dispersion shows that there is no chemical 
interaction between drug and polymers. The XRD pattern revealed 
that the drug crystallinity decreased in solid dispersion as 
compared to drug consequently the drug solubility increased. 
Therefore, it can be concluded that the aqueous solubility of poorly 
soluble drugs can be significantly improved by utilizing the solid 
dispersion technique. 
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